Who makes Part A: OSE-279 100mg?

Part A: OSE-279 100mg is developed by OSE Immunotherapeutics.

What development phase is Part A: OSE-279 100mg in?

Part A: OSE-279 100mg is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Part A: OSE-279 100mg

OSE Immunotherapeutics · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Part A: OSE-279 100mg
Sponsor	OSE Immunotherapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part A: OSE-279 100mg CI brief — competitive landscape report
Part A: OSE-279 100mg updates RSS · CI watch RSS
OSE Immunotherapeutics portfolio CI